지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 919 - 932 (14page)
이용수
초록· 키워드
오류제보하기
Purpose Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. Materials and Methods Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. Results Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ! 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. Conclusion R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ! 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Roman E / 2011 / Epidemiology of lymphomas / Histopathology 58:4~14
Pfreundschuh M / 2004 / Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL-B2 trial of the DSHNHL / Blood 104:634~641
Pfreundschuh M / 2004 / Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis(normal LDH)aggressive lymphomas : results of the NHL-B1 trial of the DSHNHL / Blood 104:626~633
Coiffier B / 2010 / Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte / Blood 116:2040~2045
Pfreundschuh M / 2008 / Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60) / Lancet Oncol 9:105~116
Pfreundschuh M / 2004 / Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL-B2 trial of the DSHNHL / Blood 104:634~641
Pfreundschuh M / 2004 / Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis(normal LDH)aggressive lymphomas : results of the NHL-B1 trial of the DSHNHL / Blood 104:626~633
Coiffier B / 2010 / Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte / Blood 116:2040~2045
Pfreundschuh M / 2008 / Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60) / Lancet Oncol 9:105~116
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
Radiation oncology journal : ROJ
2017 .01
-
Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
Cancer Research and Treatment
2015 .01
-
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
Blood Research
2018 .01
-
Analysis of treatment outcomes for primary tonsillar lymphoma
Radiation oncology journal : ROJ
2016 .01
-
고유수용성신경근촉진법 내려치기 패턴 훈련이 편측무시가 있는 뇌졸중 환자의 편측무시, 균형능력 및 일상생활수행능력에 미치는 영향: 무작위 임상 시험
대한물리의학회지
2019 .01
-
Successful remission with L-CHOP for primary mediastinal B-cell lymphoma in a young Maltese dog
Journal of Biomedical and Translational Research
2018 .12
-
HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases
Blood Research
2020 .01
-
비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과
한국임상약학회지
2015 .01
-
Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
Journal of Pathology and Translational Medicine
2022 .09
-
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2022 .10
-
항암치료를 받는 미만성거대비세포 림프종 환자에서 페그필그라스팀에 대한 효용성 평가
한국임상약학회지
2015 .01
-
Intra-patient Variability of FDG Standardized Uptake Values in Mediastinal Blood Pool, Liver, and Myocardium during R-CHOP Chemotherapy in Patients with Diffuse Large B-cell Lymphoma
Nuclear medicine and molecular imaging : NMMI
2016 .01
-
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Cancer Research and Treatment
2022 .10
-
Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
Cancer Research and Treatment
2017 .01
-
Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
Blood Research
2016 .01
-
Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
Cancer Research and Treatment
2015 .01
-
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
Cancer Research and Treatment
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0